Stocks · News reference

Vistagen Announces Topline Results From Its PALISADE-4 Phase 3 Trial Of Intranasal Fasedienol To Treat Social Anxiety Disorder; Fasedienol Did Not Achieve Its Primary Endpoint

Jun 30, 2026, 12:09 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 14, 2026, 12:50 PMBenzinga Newsdesk
VistaGen Therapeutics Q1 EPS $(0.30) Beats $(0.36) Estimate, Sales $1.476M Beat $250.000K Estimate
VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.36) by 16.67 percent. This is a 36.17 percent increase over losses of $(0.47) per share
VTGN
SEC EDGARAug 14, 2026, 12:40 PMSEC EDGAR
8-K filing — Vistagen Therapeutics, Inc. (VTGN)
Filed: 2026-08-14 AccNo: 0001628280-26-056953 Size: 241 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
VTGN
BenzingaAug 6, 2026, 12:31 PMBenzinga Newsdesk
Vistagen Says Exploratory Phase 2 Repeat Dose Study Of Fasedienol Missed Statistical Significance On Primary Endpoint (p=0.2); Reports Nominal Significance In Very Severe Social Anxiety Subgroup
VTGN
BenzingaAug 4, 2026, 2:34 PMBenzinga Newsdesk
Vistagen Therapeutics shares are trading higher after SRX Global announced that it has acquired a stake in the company.
VTGN